

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2023**

**Commission File Number: 001-38281**

---

**ERYTECH Pharma S.A.**

**(Translation of registrant's name into English)**

---

**60 Avenue Rockefeller  
69008 Lyon France**

**(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F S**

**Form 40-F E**

## INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

### Press release

On June 5, 2023, ERYTECH Pharma S.A. issued a press release to announce that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.

The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

### EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release dated June 5, 2023.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ERYTECH Pharma S.A.**

Date: June 6, 2023

By: /s/ Eric Soyer  
Name Eric Soyer  
Title: Chief Financial Officer and Chief Operating Officer

## ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

**Cambridge, MA (U.S.) and Lyon (France), June 5, 2023** - ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.

Akkadian's legal action against ERYTECH aims to obtain the adjournment of the vote on certain resolutions at the Annual General Meeting scheduled for June 23, 2023, so that ERYTECH shareholders will not be able to vote on the merger with Pherecydes.

Akkadian is also requesting the appointment of a legal expert to review the terms of the merger.

Akkadian Partners' legal action is part of their campaign to destabilize ERYTECH. To the best of ERYTECH's knowledge, Akkadian held 1,850,000 ERYTECH shares on May 24, 2023, representing around 5% of the company's share capital.

ERYTECH intends to obtain the dismissal of this legal action, which it considers unfounded, and thus enable its shareholders to vote on the merger with Pherecydes on June 23.

**About ERYTECH:** [www.erytech.com](http://www.erytech.com)

ERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.

On February 15 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phase. More detail can be found in the press release.

ERYTECH is listed on the Nasdaq Capital Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit [www.erytech.com](http://www.erytech.com)

### CONTACTS

ERYTECH  
Eric Soyer  
CFO & COO

NewCap  
Mathilde Bohin / Louis-Victor Delouvier  
Investor relations  
Nicolas Merigeau  
Media relations

+33 4 78 74 44 38  
[investors@erytech.com](mailto:investors@erytech.com)

+33 1 44 71 94 94  
[erytech@newcap.eu](mailto:erytech@newcap.eu)

